Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
December 02, 2022 17:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage...
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
October 27, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven...
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
October 04, 2022 08:56 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Connect Biopharma Holdings Limited (Nasdaq: CNTB), please note that in...
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
October 04, 2022 07:00 ET
|
Connect Biopharma Holdings Limited
All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe ADSafety and tolerability results for CBP-201 consistent with targeting...
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
October 03, 2022 16:10 ET
|
Connect Biopharma Holdings Limited
Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,tomorrow, Tuesday, October 4 SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma...
Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update
September 13, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in October 2022 – – Company to Host Conference Call Today at 4:30 p.m. ET – ...
Connect Biopharma to Report First Half 2022 Financial Results on September 13
September 01, 2022 08:00 ET
|
Connect Biopharma Holdings Limited
Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT SAN DIEGO and TAICANG, SUZHOU, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB)...
Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study
August 30, 2022 08:00 ET
|
Connect Biopharma Holdings Limited
– CBP-174 in development for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, was observed to be safe and well-tolerated – SAN DIEGO and TAICANG, SUZHOU,...
Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022
July 11, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential NDA Approval in China Remains Unchanged and is Targeted for 2025 — SAN DIEGO and...
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
June 17, 2022 16:05 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, SUZHOU, China, June 17, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”) announced on June 16, 2022,...